At what enterprise value was ANJAC BEAUTY & HEALTH acquired in 2024?

During the acquisition of ANJAC BEAUTY & HEALTH by KKR / KREFELD in 2024, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of ANJAC BEAUTY & HEALTH when it was acquired by KKR / KREFELD?

The estimated EV/EBITDA multiple for ANJAC BEAUTY & HEALTH is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was ANJAC BEAUTY & HEALTH acquired by KKR / KREFELD?

ANJAC BEAUTY & HEALTH was acquired by KKR / KREFELD in 2024.

What was the revenue of ANJAC BEAUTY & HEALTH at the time of the deal?

The revenue of ANJAC BEAUTY & HEALTH at the time of the deal is estimated to be in the range of 450M - 900M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of ANJAC BEAUTY & HEALTH during the acquisition?

ANJAC BEAUTY & HEALTH's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the ANJAC BEAUTY & HEALTH acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the ANJAC BEAUTY & HEALTH deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/anjac-ouvre-discretement-sa-porte-a-kkr-et-a-la-famille-hermes-2122840

← DATABASE

Home Database Healthcare & PharmaANJAC BEAUTY & HEALTH

10/2024

ANJAC BEAUTY & HEALTH acquired by KKR & KREFELD

FRANCE Life Sciences / Pharma & Biotech / CDMO EV 1b - 4b EUR

Context

Anjac reorganized its capital by welcoming KKR and Krefeld as minority shareholders, following a competitive process led by Rothschild & Co. The EUR450M investment allowed the exit of historical partners Andera Partners, Bpifrance, and IDIA. The Anjac family maintains a strong majority. The transaction was coupled with an extension of the existing syndicated credit line to fund future acquisitions.

As a reminder, the company had previously led a consolidation strategy by acquiring Apollo Healthcare Corp. (2022) and Stephid (2023).

ANJAC BEAUTY & HEALTH, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Anjac is a leading high-end Corporate group specialized in the formulation, manufacturing, and packaging of cosmetics, food supplements, and medical devices. Operating as a CDMO for global beauty brands, the group has grown aggressively through 10 acquisitions in 8 years. It currently operates 15+ sites globally (France, Spain, Canada) and generates nearly 50% of its revenue in North America.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with ANJAC BEAUTY & HEALTH

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
11/2025	ANJAC BEAUTY & HEALTH	HEALTH CHAIN GROUP (HCG)	SLOVENIA	Life Sciences	Anjac acquired a majority stake in HCG to accelerate its growth in the nutraceutical space. This is the 17th company to join the Anjac ecosystem. Beyond the acquisition cost, Anjac has committed to a EUR25M investment plan to expand the Velenje production site, aiming to triple its output within 12 months. The historical founders remain as operational partners.
11/2023	ANJAC BEAUTY & HEALTH	STEPHID	FRANCE	Life Sciences	ANJAC acquired STEPHID to diversify its industrial portfolio into the high-growth luxury fragrance and "niche" perfumery segments. This marks the group's 10th acquisition in six years. The integration allows ANJAC to offer "complementary expertise" (skincare + fragrance) to its existing premium client base. STEPHID benefits from ANJAC's industrial scale to fund capacity expansion while retaining its artisanal identity and current governance.
01/2022	ANJAC BEAUTY & HEALTH	APOLLO HEALTHCARE CORP.	CANADA	Life Sciences	Anjac acquired a majority stake in Apollo Healthcare Corp marking its 8th acquisition in five years. The founders, the Wachsberg brothers, remain as co-CEOs and shareholders. This deal is the cornerstone of Anjac's North American expansion, following the 2019 acquisition of Cosmetix West. The merger allows Anjac to offer global industrial capacity and specific OTC technologies (like FDA-approved sun care) to its international brand customers.

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ANJAC BEAUTY & HEALTH by KKR / KREFELD are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: kkr